Lack of the PTEN phosphatase, a frequent mutation in breast tumors, enhances Akt activation and phosphotyrosine signaling, which diminishes the efficacy of drugs that block RTK or SFK [56]. The gene discussed is AKT1; the disease is breast neoplasm.